Listed biotech Imugene was leveraging a new cancer treatment licensing deal on Wednesday morning, asking investors for a $60 million cash injection split evenly between a placement and a share purchase plan.The $30 million placement was priced at 8.4¢, a 10.6 per cent discount to its last trade price and 12.4 per cent lower than the 20-day volume weighted average price. It included a one-for-one free option with an 11.8¢ strike price and August 2026 expiry.
Imugene’s shares were halted as its house broker Bell Potter worked through the raise. It comes after the company said it would acquire the license to an allogeneic CAR T cell therapy known as azer-cel, from Precision Biosciences.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: